Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

The evolution of CLL treatment

Prof Clemens Wendtner, Dr Francesc Bosch, Prof Paolo Ghia and Prof Florence...

The evolution of CLL treatment ( Prof Clemens Wendtner, Dr Francesc Bosch, Prof Paolo Ghia and Prof Florence Cymbalista )

Investigational PD-L1–targeted immunotherapy safe for patients with triple...

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

US breast cancer cases expected to increase by as much as 50 percent by 2030

Dr Phillip Rosenberg - Division of Cancer Epidemiology and Genetics, National...

US breast cancer cases expected to increase by as much as 50 percent by 2030 ( Dr Phillip Rosenberg - Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant...

Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA )

Pembrolizumab promising for lung cancer, clinical outcomes correlate with...

Dr Edward Garon - David Geffen School of Medicine at the University of...

Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial ( Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

How to decide the treatment of CLL in 2015

Dr Marco Montillo and Dr Maria Gomes da Silva

How to decide the treatment of CLL in 2015 ( Dr Marco Montillo and Dr Maria Gomes da Silva )

ecancermedicalscience editor's choice for March 2015

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ecancermedicalscience editor's choice for March 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Expert insight: Radiation oncology with the Scientific Director of the IEO

Prof Roberto Orecchia and Prof Gordon McVie

Expert insight: Radiation oncology with the Scientific Director of the IEO ( Prof Roberto Orecchia and Prof Gordon McVie )

BRAF 'behind the scenes' in melanoma: A scientific story of discovery

Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK

BRAF 'behind the scenes' in melanoma: A scientific story of discovery ( Prof Richard Marais - Cancer Research UK Manchester Institute, Manchester, UK )

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for...

Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium

Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice ( Dr Bart Neyns - Universitair Ziekenhuis Brussels, Brussels, Belgium )

More from ecancer